FDA Panel Splits On Banning Abbott's Meridia
A U.S. Food and Drug Administration advisory panel issued a split decision Wednesday on whether Abbott Laboratories' diet pill Meridia should remain on the market, with half the panel members voting...To view the full article, register now.
Already a subscriber? Click here to view full article